Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

S. Mook, H. Bonnefoi, G. Pruneri, D. Larsimont, J. Jaskiewicz, M. D. Sabadell, G. MacGrogan, L. J. van't Veer, F. Cardoso, E. J. Rutgers

Research output: Contribution to journalArticle

Abstract

Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics for gene expression profiling on fresh frozen tumour tissue in the preparation for the prospective, multinational Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) trial. Methods: Sixty-four patients were included in six European hospitals. Fresh frozen tumour samples were shipped on dry ice to Agendia B.V., where RNA was isolated and subsequently hybridised on the 70-gene prognosis-signature (MammaPrint™). Results: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained insufficient tumour cells (

Original languageEnglish
Pages (from-to)1201-1208
Number of pages8
JournalEuropean Journal of Cancer
Volume45
Issue number7
DOIs
Publication statusPublished - May 2009

Keywords

  • Breast cancer
  • Feasibility study
  • Gene expression signatures
  • Logistics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial'. Together they form a unique fingerprint.

  • Cite this

    Mook, S., Bonnefoi, H., Pruneri, G., Larsimont, D., Jaskiewicz, J., Sabadell, M. D., MacGrogan, G., van't Veer, L. J., Cardoso, F., & Rutgers, E. J. (2009). Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. European Journal of Cancer, 45(7), 1201-1208. https://doi.org/10.1016/j.ejca.2009.01.004